VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds


Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Go
Feedback
You are here: IndiaNotes >> Research & Analysis>> Companies
The Info page of Sun Pharmaceutical Industries Ltd. shows the history of the company. It also has information about the Management, Key Executives, Board of Directors, investor returns and meetings. It also features the bankers, shareholding pattern and MF holding of Sun Pharmaceutical Industries Ltd.. Sun Pharmaceutical Industries Ltd.’s product report can also be seen here.


Share Holding Pattern for Sun Pharmaceutical Industries Ltd.

Share Holding as on :  31 Mar 2017 31 Dec 2016 30 Sep 2016
Face Value :  1.00 1.00 1.00
  No. Of Shares % Holding No. Of Shares % Holding No. Of Shares % Holding
Promoter's Holding
Indian Promoters  1,304,855,424 54.39 1,304,855,424 54.39 1,323,022,848 54.97
Sub Total  1,304,855,424 54.39 1,304,855,424 54.39 1,323,022,848 54.97
Non Promoter's Holding
Institutional Investors
Mutual Funds and UTI  128,559,256 5.36 129,203,680 5.39 102,593,976 4.26
Banks Fin. Inst. and Insurance  164,254,480 6.85 163,779,104 6.83 160,666,304 6.68
FII's  510,651,000 21.28 521,992,000 21.76 539,248,000 22.41
Sub Total  803,464,296 33.49 814,974,720 33.97 802,508,472 33.34
Other Investors
GDR/ADR  30,366 0.00 30,366 0.00 30,924 0.00
Government  380 0.00 130 0.00 130 0.00
Others  121,867,024 5.08 113,087,392 4.71 130,238,032 5.41
Sub Total  121,897,770 5.08 113,117,888 4.71 130,269,086 5.41
General Public  169,074,000 7.05 166,322,000 6.93 150,954,000 6.27
GRAND TOTAL  2,399,291,181100.00 2,399,270,188100.00 2,406,753,959100.00

Stock Recommendations for Sun Pharmaceutical Industries Ltd.

Sun Pharmaceuticals Q2FY18: Domestic business sees partial recovery; Reduce
Equirus Securities | 20 Nov, 2017
Sun Pharma’s (SUNP) 2QFY18 sales were in line with EE, while EBITDA and earnings came 10%/48% ahead of EE largely owing to lower R&D and other expense...

Sun Pharmaceutical Industries Q2FY18 in line; Recall of ANDAs could be precursor to resolution; Reduce
Prabhudas Lilladher | 16 Nov, 2017
Sun pharma retains its guidance of single-digit decline in sales with 20-22% EBITDA margin. While SUNP had 20% effective tax rate in Q1FY18 and guided...

Company update: Sun Pharmaceutical Industries
Prabhudas Lilladher | 09 Nov, 2017
Impact on Sun Pharma: With increase in R&D expenditure to 8-10% of sales from 6-8% earlier, Taro expects many derma products to be approved and launch...



Intraday Tips

What are technical calls?

View Stock Advice by: